Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • nurse-led screening
Empowering Community Liver Health: Insights from the LOCATE-NAFLD Trial on Nurse-Led MASLD Screening
Posted inClinical Updates Gastroenterology news Specialties

Empowering Community Liver Health: Insights from the LOCATE-NAFLD Trial on Nurse-Led MASLD Screening

Posted by MedXY By MedXY 08/08/2025
The LOCATE-NAFLD trial demonstrates that nurse-delivered, community-based liver screening is highly acceptable and effective for identifying high-risk MASLD patients, but faces challenges in sustainable adoption.
Read More
  • Targeting MET Amplification: Vebreltinib Shows Robust Antitumor Activity in Advanced NSCLC
  • GLIAA Trial Results: Contrast-Enhanced MRI Remains the Gold Standard for Re-irradiation Planning in Recurrent Glioblastoma
  • The Earlier, the Better: INTERACT Pooled Analysis Confirms 3-Hour Golden Window for Intensive Blood Pressure Lowering in Acute ICH
  • Beyond a Positive Result: α-Synuclein Seeding Kinetics Predict Cognitive Decline in Parkinson’s Disease
  • Plasma p-tau217 and GFAP Emerge as Robust Predictors of Alzheimer’s Progression in Down Syndrome
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in